Outpatient treatment with AZD7442 (tixagevimab/cilgavimab) prevented Covid-19 hospitalizations over 6 months and reduced symptom progression in the TACKLE randomized trial od Hobbs, FDR, Montgomery, H, Padilla, F, Simón-Campos, JA, Kim, K, Arbetter, D, Padilla, KW, Reddy, VP, Seegobin, S, Streicher, K, Templeton, A, Viani, RM, Johnsson, E, Koh, GCKW, Esser, MT

Analysis of SARS-CoV-2 Emergent variants following AZD7442 (tixagevimab/cilgavimab) for early outpatient treatment of COVID-19 (TACKLE trial) od Kijak, GH, Ahani, B, Arbetter, D, Chuecos, F, Gopalakrishnan, V, Beloor, J, Brady, T, Nguyen, A, Roe, TL, Schuko, N, Zhang, T, Hobbs, FDR, Padilla, F, Kelly, EJ, Montgomery, H, Streicher, K

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-cont... od Montgomery, H, Hobbs, FDR, Padilla, F, Arbetter, D, Templeton, A, Seegobin, S, Kim, K, Campos, JAS, Arends, RH, Brodek, BH, Brooks, D, Garbes, P, Jimenez, J, Koh, GCKW, Padilla, KW, Streicher, K, Viani, RM, Alagappan, V, Pangalos, MN, Esser, MT, TACKLE Study Group